What is it?

Auspex Diagnostic’s colorectal cancer test is a revolutionary treatment planning tool that can help stage II and III colorectal cancer patients and doctors personalize the treatment to the individual patient’s genes. Since no two patients are the alike, it is crucial that patients learn as much as possible about their tumor to determine the most suitable treatment plan. The test looks at the unique tumor gene expression data and compare it to our proprietary database to assess the risk that the individual’s cancer will return after the surgery and the efficacy of chemotherapy options.

Who is it for?

Our test is appropriate for patients with newly diagnosed stage II and III colon cancer.

What does it mean for patients and doctors?

Our colorectal cancer assays provide results specifically to the cancer patient’s tumor biology and empower cancer patients and doctors to personalize the treatment decision. Not only will the patients and doctors be able to determine whether chemotherapy will be necessary based on the predicted recurrence rate, they will also be able to know which among the different chemotherapy options will be the most effective to the patient.

Recurrence Assay

Based on the blind test data from more than 1500 patient tumor sample and clinical data using our proprietary algorithm, our cancer recurrence prediction can accurately predict the likelihood of recurrence and categorize patients into low risk and high risks groups. In 3 years post-surgery, Stage II colorectal cancer patients identified as low risk have around 12% of relapse and those identified as high risk have relapse rate of 53%. Our recurrence diagnostics assay can meaningfully identify patients with high risk tumors whom may benefit the most from adjuvant chemotherapy.

Our test yields significantly better result than those of the existing competitors on the markets who provide similar services. For example, those categorized as high risk by Genomic Health’s similar service have around 22% probability of recurrence compared to Auspex’s 53%. In other words, Auspex’s algorithm can more accurately predict the chance of relapse.

Chemotherapy Efficacy Assay

Once we determine which patients should receive further treatment based on the probability of colon cancer relapse, the next step is to determine what the best treatment option is. Auspex is the first in the world to offer chemotherapy efficacy prediction based on patient’s gene data from tumor biopsy.

Similar to the recurrence test, based on the results from the chemotherapy efficacy prediction tests oncologists and patients can better determine what chemotherapy options are the most effective and save the time and costs receiving ineffective (most time even harmful) chemo treatment. We currently have the ability to predict the efficacy of two most common colorectal cancer chemotherapy treatment methods: 5-FU and FOLFOX.

Combining both the recurrence prediction and the chemotherapy efficacy prediction diagnostics, Auspex will be able offer a complete suite of services to help oncologists to better personalize treatment for their patients.